1,544 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Bought by Orser Capital Management LLC

Orser Capital Management LLC bought a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the 3rd quarter, Holdings Channel reports. The firm bought 1,544 shares of the biopharmaceutical company’s stock, valued at approximately $704,000.

A number of other hedge funds have also modified their holdings of ALNY. Brighton Jones LLC purchased a new position in shares of Alnylam Pharmaceuticals in the 4th quarter worth $243,000. Algert Global LLC bought a new position in shares of Alnylam Pharmaceuticals in the first quarter worth about $311,000. Korea Investment CORP increased its position in shares of Alnylam Pharmaceuticals by 13.0% during the first quarter. Korea Investment CORP now owns 105,759 shares of the biopharmaceutical company’s stock worth $28,557,000 after acquiring an additional 12,156 shares during the period. Banco Bilbao Vizcaya Argentaria S.A. raised its position in Alnylam Pharmaceuticals by 2.7% during the 1st quarter. Banco Bilbao Vizcaya Argentaria S.A. now owns 22,763 shares of the biopharmaceutical company’s stock valued at $6,146,000 after purchasing an additional 609 shares in the last quarter. Finally, T. Rowe Price Investment Management Inc. raised its holdings in shares of Alnylam Pharmaceuticals by 0.8% in the first quarter. T. Rowe Price Investment Management Inc. now owns 4,418,145 shares of the biopharmaceutical company’s stock valued at $1,192,988,000 after acquiring an additional 33,696 shares in the last quarter. 92.97% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, EVP Jeffrey V. Poulton sold 3,821 shares of the business’s stock in a transaction on Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total value of $1,727,283.05. Following the completion of the sale, the executive vice president directly owned 54,052 shares of the company’s stock, valued at $24,434,206.60. The trade was a 6.60% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Yvonne Greenstreet sold 15,650 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $453.69, for a total value of $7,100,248.50. Following the transaction, the chief executive officer directly owned 65,409 shares in the company, valued at approximately $29,675,409.21. This trade represents a 19.31% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 60,328 shares of company stock worth $27,288,993. 1.50% of the stock is currently owned by company insiders.

Alnylam Pharmaceuticals Trading Up 0.2%

NASDAQ:ALNY opened at $392.10 on Thursday. The company has a current ratio of 2.54, a quick ratio of 2.49 and a debt-to-equity ratio of 4.45. Alnylam Pharmaceuticals, Inc. has a 12-month low of $205.87 and a 12-month high of $495.55. The firm has a market cap of $51.80 billion, a PE ratio of 1,633.75 and a beta of 0.30. The stock has a fifty day moving average price of $448.60 and a 200 day moving average price of $409.30.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. Morgan Stanley boosted their target price on shares of Alnylam Pharmaceuticals from $405.00 to $475.00 and gave the stock an “equal weight” rating in a report on Monday, October 6th. JPMorgan Chase & Co. decreased their price objective on shares of Alnylam Pharmaceuticals from $475.00 to $473.00 and set an “overweight” rating for the company in a research note on Monday, October 13th. BMO Capital Markets raised their target price on Alnylam Pharmaceuticals from $450.00 to $470.00 and gave the stock an “outperform” rating in a report on Friday, September 5th. Bank of America upped their price objective on shares of Alnylam Pharmaceuticals from $453.00 to $520.00 and gave the stock a “buy” rating in a research report on Wednesday, September 17th. Finally, Royal Bank Of Canada increased their target price on Alnylam Pharmaceuticals from $435.00 to $500.00 and gave the company an “outperform” rating in a research report on Friday, September 19th. Twenty-three analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $477.44.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.